Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 173

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study

Mochizuki, Hiroyuki, Kusuda, Satoshi, Okada, Kenji, Yoshihara, Shigemi, Furuya, Hiroyuki, Simões, Eric A. F., Asanuma, Hideomi, Yoshida, Hiroshi, Katayose, Masahiko, Imamura, Takashi, Suzumura, Hiroshi, Honma, Youko, Medical, Jichi, Maruyama, Kenichi, Ohki, Yasushi, Ozasa, Koji, Nariai, Akiyoshi, Uchiyama, Atsushi, Uryu, Hideko, Hosono, Shigeharu, Kondo, Masatoshi, Kawase, Yasuharu, Ikeda, Kazunari, Ikeda, Kazunari, Naito, Atsushi, Minami, Yuki, Nakamura, Tomohiko, Baba, Atsushi, Nagayama, Yoshihisa, Kaneda, Hisashi, Ohki, Shigeru, Shiraii, Masami, Henmi, Yuto, Suzuki, Chizuko, Ieda, Kuniko, Tanaka, Taihei, Kono, Yoshinori, Nisizawa, Kashiro, Niwa, Fusako, Ito, Hisato, Tokunaga, Yasuyuki, Takada, Yoshinobu, Nishikawa, Yoshihide, Nagata, Ikuo, Kajino, Yasuhisa, Watabe, Shinichi, Yoshio, Hiroyuki, Takahashi, Nobumasa, Sasaki, Nobutaka, Hayashidani, Michiko, Tateishi, Hiroshi, Matsushita, Kenji, Nakamura, Masatoshi, Nakayama, Hideki, Yamamoto, Go, Kanemitsu, Noriaki, Takayanagi, Toshimitsu, Sato, Ayumi, Ibara, Satoshi · 2017 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Respiratory syncytial virus (RSV) induces not only infantile recurrent wheezing but also potentially atopic asthma. OBJECTIVES: To test the effect of RSV infection on development of subsequent atopic asthma, we evaluated whether palivizumab, an anti-RSV monoclonal antibody, by preventing severe RSV disease in the first year of life, could impact subsequent recurrent wheezing and atopic asthma at 6 years of age. METHODS: During the 2007 to 2008 RSV season, the decision to administer palivizumab was made based on standard medical practice and an observational prospective multicenter (n = 52) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed from 0 to 3 years (preceding Committee on Recurrent Wheezing study). The 52 investigators at hospitals then followed these subjects until 6 years of age, reported here (Effects of Preventive Treatment for Respiratory Syncytial [RS] Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants; Scientific Committee for Elucidation of Infantile Asthma). Parents of study subjects reported the infants' physicians' assessment of recurrent wheezing, using a report card and a novel mobile phone-based reporting system using the Internet. The primary endpoint was the incidence of atopic asthma. MEASUREMENTS AND MAIN RESULTS: Of 444 preterm infants enrolled, 349 received palivizumab during the first year of life. At 6 years, atopic asthma was not different in the groups: 15.3 and 18.2% of infants in the treated and untreated groups, respectively (P = 0.57). On the other hand, physician-diagnosed recurrent wheezing was observed in 15.3 and 31.6% in the treated and untreated groups, respectively (P = 0.003). CONCLUSIONS: Palivizumab prophylaxis administered to preterm infants did not suppress the onset of atopic asthma but resulted in a significantly lower incidence of recurrent wheezing during the first 6 years. Clinical trial registered with www.clinicaltrials.gov (NCT 01545245).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201609-1812oc

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 173

Metadata

Authors
Mochizuki, H., Kusuda, S., Okada, K., Yoshihara, S., Furuya, H., Simões, E. A. F., Asanuma, H., Yoshida, H., Katayose, M., Imamura, T., Suzumura, H., Honma, Y., Medical, J., Maruyama, K., Ohki, Y., Ozasa, K., Nariai, A., Uchiyama, A., Uryu, H., Hosono, S., Kondo, M., Kawase, Y., Ikeda, K., Ikeda, K., Naito, A., Minami, Y., Nakamura, T., Baba, A., Nagayama, Y., Kaneda, H., Ohki, S., Shiraii, M., Henmi, Y., Suzuki, C., Ieda, K., Tanaka, T., Kono, Y., Nisizawa, K., Niwa, F., Ito, H., Tokunaga, Y., Takada, Y., Nishikawa, Y., Nagata, I., Kajino, Y., Watabe, S., Yoshio, H., Takahashi, N., Sasaki, N., Hayashidani, M., Tateishi, H., Matsushita, K., Nakamura, M., Nakayama, H., Yamamoto, G., Kanemitsu, N., Takayanagi, T., Sato, A., & Ibara, S.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2017-07-01
Volume
196
Issue
1
Pages
29-38
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2586644068
Cited by
173
References
2
FWCI
17.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. https://app.cochat.ai/papers/10.1164/rccm.201609-1812oc
The paper
Mochizuki, H., Kusuda, S., Okada, K., Yoshihara, S., Furuya, H., Simões, E. A. F., Asanuma, H., Yoshida, H., Katayose, M., Imamura, T., Suzumura, H., Honma, Y., Medical, J., Maruyama, K., Ohki, Y., Ozasa, K., Nariai, A., Uchiyama, A., Uryu, H., . . . Ibara, S. (2017). Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201609-1812oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.